Nivolumab for locally advanced and metastatic cutaneous squamous cell carcinoma (<scp>NIVOSQUACS</scp> study)—Phase <scp>II</scp> data covering impact of concomitant haematological malignancies

Abstract

This study demonstrated robust clinical efficacy of nivolumab in patients with locally advanced and metastatic cSCCs and a tolerability comparable to data of other anti-PD-1 antibodies. Favourable outcomes were obtained despite involving the oldest hitherto reported study cohort for anti-PD-1 antibodies and a significant proportion of CHM patients prone to high risk tumours and an aggressive course otherwise typically excluded from clinical trials.